C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes

scientific article published on 3 December 2015

C-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1042755389
P356DOI10.1186/S12872-015-0153-7
P932PMC publication ID4668670
P698PubMed publication ID26631004
P5875ResearchGate publication ID285640229

P50authorHarry P. SelkerQ60057895
Gordon S. HugginsQ114427846
Joni R. BeshanskyQ124810388
P2093author name stringRobin Ruthazer
Inga Peter
Hadeel Alkofide
Jayanta T Mukherjee
Madhab Ray
P2860cites workC-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?Q33678964
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.Q33898507
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trialQ34204296
Role of metabolically active drugs in the management of ischemic heart diseaseQ35631392
Metabolic manipulation in ischaemic heart disease, a novel approach to treatmentQ35745797
Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study GroupQ36244558
The principles of metabolic therapy for heart diseaseQ36340878
Inflammatory biomarkers in acute coronary syndromes: part II: acute-phase reactants and biomarkers of endothelial cell activationQ36402102
The clinical application of metabolic therapy for cardiovascular diseaseQ36873628
Insulin resistance and inflammation markers in myocardial infarctionQ36975794
Glucose-insulin-potassium revived: current status in acute coronary syndromes and the energy-depleted heartQ38086415
Effects of glucose, insulin and potassium infusion on tissue metabolic changes within first hour of myocardial infarction in the baboonQ40320383
Effects of glucose and fatty acids on myocardial ischaemia and arrhythmiasQ40619598
C-reactive protein and lesion morphology in patients with acute myocardial infarctionQ44497548
Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trialQ44574635
Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarctionQ44752428
Effect of glucose-insulin-potassium infusion on plasma free fatty acid concentrations in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarctionQ45148891
Relationship between size of myocardial infarctions assessed by delayed contrast-enhanced MRI after primary PCI, biochemical markers, and time to interventionQ45152229
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trialQ45238837
Effect of glucose-insulin-potassium (GIK) infusion on biomarkers of cardiovascular risk in ST elevation myocardial infarction (STEMI): insight into the failure of GIK.Q46973471
C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarctionQ47191457
Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapyQ47391014
Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for ST-elevation myocardial infarction.Q51095098
Role of Inflammation in AtherosclerosisQ58492168
Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarctionQ67816268
Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatmentQ71703487
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 yearQ72351090
C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarctionQ73606387
Glucose-insulin-potassium for acute myocardial infarction: remarkable results from a new prospective, randomized trialQ77592639
Glucose-insulin-potassium (GIK) for acute myocardial infarction: a negative study with a positive valueQ78105403
Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical reportQ79421557
Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imagingQ81406260
Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive proteinQ82725159
Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-IIQ83186798
P921main subjectacute coronary syndromeQ266018
P304page(s)163
P577publication date2015-12-03
P1433published inBMC Cardiovascular DisordersQ15753126
P1476titleC-Reactive protein reactions to glucose-insulin-potassium infusion and relations to infarct size in patients with acute coronary syndromes
P478volume15

Search more.